files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346
109
Views
2
Downloads

Immunohistochemical Detection of Alpha-Methyl-Co-Racemase (AMACR) in Adenocarcinoma of Prostate

Mohammed S. Abdelaziz, Hagir E. Mohagir, Ali Yousif Babiker, Mohamed A. Alsahli, Saleh A. Almatroodi and Arshad H. Rahmani
Page: 707-710 | Received 21 Sep 2022, Published online: 21 Sep 2022

Full Text Reference XML File PDF File

Abstract

The aim of study was to evaluate the expression pattern of Alpha-methylacyl-CoA Racemase (AMACR) in prostate tumors. In order to examine the relationship between AMCAR expression and tumor, we analyzed a total of 10 cases of benign prostatic hyperplasia and 20 cases of prostate adenocarcinoma . Expressions pattern of AMCAR were analysed and found that only one case (10%) of benign prostatic hyperplasia showed expression whereas 19 cases (95%) of prostate adenocarcinoma showed expression at different levels of intensity. The difference in expression pattern among benign prostatic hyperplasia and prostate adenocarcinoma was statically significant (p>0.05). Expression profile were further categorised according to grade of the tumor and found that AMCAR was expressed in 4 (100%), 6 (100%) and 9 (90%) in well, moderate and poor differentiated prostate adenocarcinoma respectively. This difference of expression among the different types of grade was statistically insignificant (p>0.05). Our results concluded that AMCAR is a valuable diagnostic and prognostic marker of prostate cancer and one of the vital factors in pathogenesis of prostrate adenocarcinoma.


How to cite this article:

Mohammed S. Abdelaziz, Hagir E. Mohagir, Ali Yousif Babiker, Mohamed A. Alsahli, Saleh A. Almatroodi and Arshad H. Rahmani. Immunohistochemical Detection of Alpha-Methyl-Co-Racemase (AMACR) in Adenocarcinoma of Prostate.
DOI: https://doi.org/10.36478/rjmsci.2016.707.710
URL: https://www.makhillpublications.co/view-article/1815-9346/rjmsci.2016.707.710